The incidence of bladder cancer is set to increase by 11% in the seven major pharmaceutical markets between 2004 and 2012. Current therapy yields notable response rates yet 80% of patients with superficial bladder cancer will relapse and there has been no advance in patient survival in the last decade. This brief examines current treatment issues and future directions in the bladder cancer market.
Scope
Overview of disease including epidemiology, biology of bladder cancer, staging and prognostic variables
Current treatment options and clinical controversies
Key recommendations in the areas of greatest unmet need, including superficial and invasive bladder cancer
Profiles of key bladder cancer agents in late-stage development. Opinions from key bladder cancer specialists
Highlights
There have been no improvements in patient survival over the last decade. In the setting of advanced disease combination regimens using Eli Lillys Gemzar are set to replace the current gold standard M-VAC, but this is likely to be due to an improved toxicity profile rather than increased efficacy.
We believe that the integration of new, targeted therapies in combination with chemotherapy may hold promise for preventing the progression to invasive bladder cancer. The most appropriate combination remains to be defined.
Optimal treatment will be dependant on an accurate assessment of disease prognosis. Thus the development of molecular markers which can predict patients at greatest risk of progression will be pivotal to improving patient survival.
Reasons to Purchase
Identify future market opportunities by examining current unmet needs and how current therapy fails to improve survival for bladder cancer patients
Understand the epidemiology and current clinical treatments in bladder cancer
Plan new product development based on an understanding of physician expectation of molecular- targeted therapy for bladder cancer
